UnknownNCT00514345
CYP3A5 Gene as a Risk Factor for Kidney Damage in Young Patients With Cancer Treated With Ifosfamide
Studying Embryonal rhabdomyosarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Children's Cancer and Leukaemia Group
- Principal Investigator
- Gareth VealUniversity of Newcastle Upon-Tyne
- Intervention
- gene expression analysis(genetic)
- Enrollment
- 300 enrolled
- Eligibility
- 20 years · All sexes
- Timeline
- 2007
Study locations (21)
- Our Lady's Hospital for Sick Children Crumlin, Dublin, Ireland
- Birmingham Children's Hospital, Birmingham, England, United Kingdom
- Bristol Royal Hospital for Children, Bristol, England, United Kingdom
- Addenbrooke's Hospital, Cambridge, England, United Kingdom
- Leeds Cancer Centre at St. James's University Hospital, Leeds, England, United Kingdom
- Leicester Royal Infirmary, Leicester, England, United Kingdom
- Royal Liverpool Children's Hospital, Alder Hey, Liverpool, England, United Kingdom
- University College Hospital, London, England, United Kingdom
- Great Ormond Street Hospital for Children, London, England, United Kingdom
- Royal Manchester Children's Hospital, Manchester, England, United Kingdom
- Sir James Spence Institute of Child Health at Royal Victoria Infirmary, Newcastle upon Tyne, England, United Kingdom
- Queen's Medical Centre, Nottingham, England, United Kingdom
- Oxford Radcliffe Hospital, Oxford, England, United Kingdom
- Children's Hospital - Sheffield, Sheffield, England, United Kingdom
- Southampton General Hospital, Southampton, England, United Kingdom
- +6 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00514345 on ClinicalTrials.govOther trials for Embryonal rhabdomyosarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT06541262Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid TumorsMilton S. Hershey Medical Center
- RECRUITINGPHASE1NCT04337177Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid TumorsValent Technologies, LLC